The authors describe the discovery of a new class of inhibitors to an essential Streptococcus pneumoniae cell wall biosynthesis enzyme, MurF, by a novel affinity screening method. The strategy involved screening very large mixtures of diverse small organic molecules against the protein target on the basis of equilibrium binding, followed by iterative ultrafiltration steps and ligand identification by mass spectrometry. Hits from any affinity-based screening method often can be relatively nonselective ligands, sometimes referred to as "nuisance" or "promiscuous" compounds. Ligands selective in their binding affinity for the MurF target were readily identified through electronic subtraction of an empirically determined subset of promiscuous compounds in the library without subsequent selectivity panels. The complete strategy for discovery and identification of novel specific ligands can be applied to all soluble protein targets and a wide variety of ligand libraries. (Journal of Biomolecular Screening 2006:743-754) 
INTRODUCTION

H
IGH-THROUGHPUT SCREENING (HTS) plays a variety of roles in drug discovery. Most commonly, the function of HTS is to conduct a methodical search for potential drug leads for established and well-understood targets through cell-based or purified protein-based assays. 1, 2 More recently, techniques such as genomics, proteomics, and reverse chemical genetics (the elucidation of target function through identification of smallmolecule ligands to that target and subsequent study of their phenotypic effects) have enabled target discovery and validation on a vastly expanded scale. 3 This, in turn, has created a requirement for improvements in HTS speed and efficiency. Genomics and proteomics discovery paradigms have inspired the cloning, expression, and purification of targets of interest well before the specific function is understood, and affinity-based HTS techniques that do not depend on target function for their readout then can be used to discover specific ligands to the targets. For example, proteins essential for survival of a bacterial organism but not essential for human cellular function can be identified genetically and then interrogated by a chemical library using affinity screening to identify promising target/lead pairs. 4 Leads thus identified can then be introduced back into the cell for use as a probe of the target's cellular function, for further target validation, and for lead optimization.
A number of fairly efficient high-throughput affinity-based techniques have been described for discovering small-molecule ligands and are in academic and commercial use. Gold surfaceimmobilized fragments from a combinatorial chemistry-derived library coupled with surface plasmon resonance detection technology are used by Graffinity Pharmaceutical Design GmbH (Heidelberg, Germany). 5 The ATLAS TM technology, from Anadys Pharmaceuticals, Inc. (San Diego, CA), uses automated homogeneous fluorescence monitoring to detect unfolding transitions of appropriately labeled proteins; this is a homogeneous technique because no separation step takes place between the steps of binding and readout. Another homogeneous fluorescence technique, used by 3-Dimensional Pharmaceuticals, measures shifts in target melting temperature. 6 Hydrogen/ deuterium exchange, monitored by protein mass spectrometry, can also be used to monitor ligand binding-induced shifts in protein stability, and this technique shows promise for efficient screening of small-molecule libraries. 7 Several nuclear magnetic resonance (NMR)-based techniques have been applied to a variety of targets. [8] [9] [10] [11] In addition, a number of heterogeneous affinity techniques (involving a separation step) that include mass spectrometry-based readout also have been described. These include the use of coupled pulsed ultrafiltration/mass spectrometry, [12] [13] [14] noncoupled ultrafiltration, 15, 16 restricted access phase chromatography, 17 size exclusion chromatography, 16, [18] [19] [20] capillary electrophoresis, 21, 22 and target shift mass spectrometry. 23 Each of these techniques has strengths and limitations with respect to assay development time, screening throughput, specialized protein requirements, and specialized library design requirements. 14, 16, 24 Particular consequences to techniques involving component immobilization include the requirement for protein or compound tagging and the attendant possibility for artifacts in protein character (alteration in conformation, inactivation of key residues) or limitations in library chemistry.
A general challenge for affinity-based screening techniques is how to screen large compound collections in a reasonable time frame. Many of the techniques described bog down when hundreds of thousands of library compounds are screened per target, yet a consensus of operational and theoretical studies from HTS over the past 10 years has indicated that screening is well served by maximizing library size. [25] [26] [27] Until the rules of diversity are thoroughly understood and small libraries that span the range of chemical effector space can be synthesized or assembled from existing stocks, the chances of finding a good starting point for medicinal chemistry optimization will increase as the number of compounds screened increases. However, as the library size and number of targets increases, a general concern about affinity-based screening is that the identification of a large number of nonselective, promiscuous compounds can be overwhelming so that the best, selective compounds may be overlooked.
To address these concerns, our goal was to develop an HTS method that would be efficient and robust enough to allow study of many targets against very large libraries on the basis of affinity, with an adjustable stringency and method for removing promiscuous compounds that bind nonselectively to proteins in general. Here we describe application of our method to screen for compounds that bind to a bacterial target protein. The method enabled discovery of a novel compound series that binds specifically to and inhibits the UDP-MurNAc-pentapeptide synthetase enzyme MurF, which catalyzes the final step in the synthesis of the bacterial peptidoglycan cell wall precursor, addition of D-Alanine-D-Alanine to UDP-MurNac-tripeptide. Targeting the UDP-MurNAc-pentapeptide synthetic pathway has been a goal of antibacterial research for years. 28 Two chemically related compounds were rapidly determined to be the most potent and selective ligands in a library of 123,405 compounds, screened in large pools of ~2700 compounds per mixture with a stringency set by the protein concentration of 10 µM. The identification of this novel MurF inhibitor series led to a medicinal chemistry optimization effort described in detail elsewhere. 29 
RESULTS
Primary screening strategy
The general method for affinity selection/mass spectrometry (ASMS) is shown in Figure 1 . In ASMS, the target concentration is set at 10 µM so that at equilibrium, ligands with affinities no weaker than K D~1 0 µM will be significantly bound and, therefore, retained in the ultrafiltration steps. The minimal concentration of each small molecule is dictated by the eventual need to detect ligands by mass spectrometry after several cycles of ultrafiltration and subsequent extraction. To ensure detection just above baseline for the vast majority of compounds, which vary in inherent ionization properties and efficiency of mass spectrometric visibility, the starting compound concentration is set at 1.5 µM per compound. The mixture size is set to be as large as possible to minimize the quantity of protein required and increase the throughput for screening the maximum number of compounds while still trying to maintain a condition of excess free target. By screening ~2700 compounds per mixture, the combined small-molecule concentration is ~4 mM, or 400 times in excess of the target protein. However, in a diverse small-molecule mixture of 2700 compounds, very few compounds are anticipated to have K D < 10 µM, or even K D < 100 µM, so that the probability of competition binding leading to the loss of a high-affinity ligand is very low. For example, in small-molecule screening using an NMR affinity screening method, 8 the frequency of compounds with K D < 1 mM is ~0.25% (Phil Hajduk, personal communication, 2005) . Therefore, if there are on average ~7 very weak ligands (0.25% of 2700) per mixture, in aggregate, these are in equimolar concentration with the target protein, and the protein will still be mostly unbound.
Multiple rounds of selection are performed to increase the signal over background. When 90% of the volume is filtered, the initial equilibrium-bound fraction of each compound is retained, in addition to a constant residual 10% (unbound) from the remaining volume. Although unbound ligands are being depleted during filtration, the initial equilibrium quantity of bound ligand is maintained because the protein concentration is also increasing at the same rate. For example, a ligand with K D = [protein] will be 50% bound initially. As half the volume has passed through the filter, half of the free ligand has passed through (or 25% of the total), but now [protein] = 2K D , so 66% of the remaining 75% of the ligand will be bound, which is equal to 50% of the original ligand still bound. In other words, the use of ultrafiltration results in a continuous equilibrium such that enrichment can be achieved on the basis of equilibrium rather than dissociation rate, particularly for weak binding compounds with K D values in the low micromolar range (which typically equilibrate on a timescale that is faster than the volume reduction). After each round of selection, the volume is restored to the initial volume, but so is the initial protein concentration. Successive rounds of selection result in exponential enrichment of ligands such that the final concentrations will be inversely correlated to the K D of each ligand (i.e., compounds with the highest affinity, or lowest K D , will be the most abundant).
By adjusting the target concentration, the screening stringency can be altered. Given the starting concentration of each compound in the mixture and the postselection processing for mass spectrometric detection, the ASMS method is designed so that compounds that cannot bind (i.e., those that have K D > 10×[protein]) are just below the limit for detection in the mass spectrometer, whereas those with the desired affinity (K D[ protein]) will be > 10× above the background as the only remaining peaks. In practice, for the majority of the library, a compound with affinity equal to the protein concentration will be robustly identified, whereas a weaker binder will show less consistent results. However, compounds with weaker K D values, on the order of 3-fold above the protein concentration, also can be readily observed when the compounds are especially well extracted and/or ionized in the mass spectrometer (data not shown).
After affinity selection, an organic solvent extraction step separates ligands from the protein and prepares them for electrospray mass spectrometric analyses in both positive and negative ionization modes. The protocol was experimentally selected for efficient extraction of the widest range of drug-like 30 and lead-like 31, 32 compounds in the compound collection. The mass spectra of samples are processed and either inspected visually or by the aid of ASAE.NET analysis software (see the accompanying article by Comess et al 33 ) . Peaks that stand out by comparison with the local background are identified as primary hits. In addition, spectra obtained with other compound mixtures are examined to determine whether the m/z ratio of identified peaks are unique to a particular mixture. Peaks with the same m/z ratio in spectra from multiple compound mixtures are generally artifacts, such as contaminants in the protein preparation. To ensure that hits are not missed, peaks are picked even if they are barely enriched over background. The false positives inherent in the noise near background are easily eliminated in the subsequent deconvolution step. The peaks of interest are converted into a list of potential ligands (hits). Each peak, however, corresponds on average to 6 mass-redundant compounds, with only 1 typically being responsible for the apparent binding. Therefore, only ~17% of the primary hits are expected to demonstrate binding in subsequent retesting and deconvolution experiments.
The primary screen for MurF ligands used 45 mixtures of approximately 2700 compounds each and was run in a single day. A duplicate screen was run on a second day. In the MurF screen, 434 peaks were identified as potential hits from the first experiment, ranging in monoisotopic mass from 249.09 to 773.50 atomic mass units (amu). The number of peaks in each of the 45 mixtures ranged from 1 to 35. In the duplicate screen, 390 peaks were identified as potential hits, with 157 peaks overlapping between the duplicate screens. Compounds from the overlapping peaks were assembled into a primary hit list of 1147 compounds for subsequent retesting and confirmation.
Retesting and deconvolution strategy
In the retesting and deconvolution phase of the procedure, new compound mixtures were made based on the results of primary screening. These contained from 9 to 14 compounds and no monoisotopic mass redundancy. Because most mass spectrometric peaks picked as hits in the primary screen contain more than 1 compound, and only 1 compound per peak is likely to be a binder, the nonmass redundant retest mixtures are unlikely to contain more than a few bona fide ligands, so once again target excess is maintained. Both the initial (R0, prior to first round of filtration) and final (R3, after 3 rounds of selection) mixtures are sampled. By measuring the signal intensity or signal/background ratio for a compound before and after selection, the K D value can be estimated.
Promiscuous compound filter
In activity-based HTS campaigns, secondary counterscreens frequently are applied to exclude artifacts, such as compounds that inactivate the substrate or detection method rather than the target of interest. One advantage of an affinity-based HTS strategy is that there are no additional reagents, substrates, or cofactors in the assay to increase the potential for false positives due to such artifacts. In addition, any false-positive ligands that do occur should be similar for all targets because the assay format and detection method is identical for every target screened. Aggregated compounds that cannot pass through the 10,000-Da molecular weight cutoff filter are an example. Interestingly, ASMS will not detect reactive compounds bound covalently to a target protein (which can be common as nuisance hits in activity-based screens) because of the requirement in ASMS for ligands to be dissociated before mass spectrometric (MS) detection. However, compounds that have promiscuous or nonspecific affinity for a variety of proteins are a potential problem for HTS in general, and ASMS is no exception in this regard. Furthermore, although certain chemotypes seem to recur as nonspecific hits in HTS (activity or affinity), some individual members within a class can have just enough selectivity to hit in very few screens due to the relatively high stringency. This can lead to a significant waste of time trying to optimize these into quality lead compounds, as the series can rarely attain drug-like selectivity.
After screening and deconvolution of primary hits from dozens of targets by our ASMS technique, it became apparent that the frequency of compound overlap between targets was high, but aggregated compound occurrences were very low. Aggregated compounds could be detected in 2 ways: (1) by showing apparent binding to every target in the primary screen and (2) by showing a very high retention in the absence of protein. Nonselective but nonaggregated ligands were discovered as expected and exhibited a range of K D values as measured in deconvolution experiments. Therefore, simply adjusting the stringency or rejecting hits above a certain K D threshold cannot easily eliminate these nonselective ligands. Many distinct structural classes or chemotypes were observed, but a phenylsulfonamide series represented by compounds 1 through 3 appeared most often. Compound 1 has been resolved as a ligand for 10 distinct protein targets out of 16 target screens run, compound 2 as a ligand for 13 out of 40 screens, and compound 3 as a ligand for 12 out of 45 screens. The apparent K D value depends on the particular target, with compound 2, for example, having affinities ranging from 1 to 30 µM for different targets.
We reasoned that a low-stringency ASMS screening campaign might allow identification of nonselective ligands. By deprioritizing these ligands in subsequent high-stringency screening campaigns, we could identify the most selective ligands.We also observed that different protein targets varied widely in their propensity to bind promiscuous ligands. This suggests that targets could be profiled for selective chemical tractability. If the compound library was profiled for the nonspecific ligands once, then the information could be used for all other screens, to prioritize compounds for follow-up and to profile targets for the likelihood that they can be bound selectively by small molecules.
Blood serum, whose principal component is albumin, is known for its ability to bind reversibly to a very large variety of ligands. For this reason, serum was employed as a model target for general nonspecific binding. Although serum protein binding can be engineered out in a medicinal chemistry campaign on a given series, and serum protein binding is not intrinsically a criterion for deprioritizing a particular lead compound, in the case of affinity-based screening, the leads most likely to be optimized into drugs should be those with selective affinity for a target. Subsequent medicinal chemistry for potency, pharmacokinetic, and other properties will likely result in some degree of binding to serum proteins, which needs to be considered in the context of the rest of the properties, but candidates with target-selective binding interactions make easier starting points for a medicinal chemistry campaign than do nonselective ligands because nonselective hydrophobicity tends to increase during optimization. 31, 32, 34 Our goal was to divide the screening library into 2 populations, a set of compounds with extremely low probability of promiscuous binding and as small a set as possible that would contain all serum protein ligands under our ASMS conditions; the latter is called the Promiscuous Compound Filter (PCF) list. To do this, screening was performed at several serum concentrations and in several replicates to gather sufficient data for analysis. Figure 2 shows statistics from running 45 mixtures containing a total of 123,405 compounds in duplicate against prepared serum diluted to 2%, 10%, and 20% of its neat concentration (the latter corresponding to approximately 0.1 mM albumin, thus providing the desired low stringency). All compounds whose exact monoisotopic mass falls within 0.5 amu of a peak were annotated electronically.
33 Figure 2A shows the percentage of compounds on the MurF primary hit list that overlap with the primary hit list for each serum screen and the percentage of the entire library within the serum hit list. Note that these range from 44% to 50%, so that in each case, the serum screen is hitting MurF ligands with higher than random (13%-15%) frequency. If MurF bound only selective ligands, then the serum list would be irrelevant, and one would expect the percentage of MurF hits on the serum list to be no higher than that determined by random chance based on the percentage of the entire library contained on the serum hit list. The decision to use the combined list of 36,748 compounds that occur at least once in any of the serum screens as (Fig. 2B) , we included all compounds within 0.5 m/z units to further ensure that the PCF list contained all possible serum protein ligands.
MurF lead discovery
To efficiently identify compounds of interest for further study in biochemical or cell-based assays, the candidate ligands remaining after promiscuous compound filtering were deconvoluted in small non-mass-redundant mixtures. The 8 deconvoluted hits are shown in Table 1 , along with their enzyme inhibition values. The 2 best ligands (compounds 4 and 5) also are structurally related and were discovered in different initial screening mixtures. ASMS binding data are shown in Figure 3 . Both compounds were ionized in the negative ion mass spectrometry mode, and the characteristic halogen isotope patterns at M + 2 for the monochloro (4) and dichloro (5) functional groups are evident both in primary screening (Fig. 3A) and deconvolution testing (Fig. 3B,C) . Signal intensities are much weaker in primary screening than in deconvolution, most likely because of ionization of the very low levels (≤ 1 pmol) of several thousand nonligands remaining in a mixture after affinity selection. Nevertheless, the signal is still adequate so that these and other hits were selected in the primary screen. Subsequent structureactivity relationship (SAR) studies were conducted to increase the potency of this series, and several analogs with IC 50 values in the 20-to 70-nM range have been synthesized. 29 Additional biophysical studies using x-ray crystallography and NMR have confirmed the active site binding and specificity of the compound series. 35, 36 DISCUSSION ASMS combined with a novel promiscuous ligand-filtering procedure led to the discovery of a potent series of MurF inhibitors. The lead discovery methods were highly parallel, robust, and efficient. One key to success of this very straightforward screening process is the large number of compounds in each primary screening mixture. Without this feature, protein consumption would be prohibitive, and the logistics of manipulating a larger number of smaller mixtures would be difficult. Although larger mixtures of compounds result in an increase in mass redundancy and therefore a concomitant increase in the number of compounds that need to be retested and deconvoluted, the overall efficiency is greatly increased.
There are approximately 2700 compounds per primary screening mixture, and the readout is in essence multiplexed; the ligands are individually ionized and identified in the mass spectrometer according to their exact mass positions. The readout, however, does not unambiguously identify compounds, as multiple compounds in a single mixture may have the same mass (i.e., a particular peak may correspond to as many as 31 compounds with closely related masses). The protein excess over individual compounds coupled with the rarity of potent ligands within a randomly assembled library minimizes competition between ligands for available sites. In the theoretical case which the number of ligands overwhelms the number of target sites, the apparent affinity of ligands will be reduced. Caution must be used in assembling libraries of either biomolecular or combinatorial origin because these could have problems with weak binding as a class. 25, 26 This could result in significant competition, making individual higher affinity ligands undetectable. With a sufficiently diverse collection of compounds, this is not a concern. The retesting/deconvolution phase of screening uses small mixtures of non-mass-redundant compounds. A balance of stringent rejection criteria and emphasis on reduction of false negatives is maintained during this phase. Although in theory, 90% of the compound is lost in each round of selection in the absence of protein, an actual protein-free selection is performed for each mixture to increase accuracy and decrease false positives. At one extreme, compounds that form large aggregates 37, 38 could appear to be ligands in the proteincontaining selection even if they cannot, in fact, bind to the target, but such compounds also will demonstrate an equivalent fraction retained per round of selection in the absence of protein. When this occurs, the fraction bound (equation (3)) calculates approximately to 0, and no K D estimate is made. In addition, the set of 4 spectra [R0(+), R0(-), R3(+), and R3(-)] for each putative deconvoluted ligand is scored visually for verification of appropriate ligand behavior. Based on a survey of several thousand randomly chosen compounds, approximately 80% of the library compounds are visible under the experimental conditions (data not shown). The remainder may be poorly extracted, show poor sensitivity to electrospray ionization, or have an incorrectly assigned structure and formula due to degradation or rearrangement during storage. Although a limitation of the method is its bias toward generally more MS visible compounds, compound structural series that are identified through traditional HTS techniques, such as fluorescence polarization assay, are also discovered in ASMS screens. 39 The total time required for the screen from primary screening through retesting and deconvolution is under 6 weeks, and it can be further reduced by automation. 33 The concept of promiscuous compound filtering was implemented for ASMS screening as a means to prioritize hits based on their potential value as drug leads, but it also may be used to prioritize targets. Note that 65% of the MurF hit resulted in overlap with the total combined PCF list. In 34 ASMS screens run against targets across several areas of pharmaceutical research, we have observed that 36% to 92% of primary hits for individual protein targets overlap with compounds on the PCF list. Because targets vary widely in their tendency to bind compounds on the PCF list, it is tempting to believe that targets with higher frequency of overlap with the PCF list will pose a more difficult challenge in drug discovery either because of a similarity to serum proteins or a binding site that is ideal for promiscuous compounds in general.
Medicinal chemistry directed at these kinds of targets, even with initial leads that show some binding selectivity, may result in optimized compounds that have undesired binding affinity for other proteins if the nature of the active site on the target is inherently similar to other proteins in the ability to bind promiscuous classes of small molecules. Targets that result in hit lists with very high overlap with the PCF list may be considered less desirable even if a few selective hits are discovered, although this is only speculation at this point. The difference in the propensity of various proteins to bind to the major classes of promiscuous compounds is one of the more interesting results of these experiments and would require more study to fully understand all of the ramifications on the drugability of different kinds of targets.
Although there must be "innocent bystanders" present in the PCF list, the mass redundancy of the primary screening mixtures makes this unavoidable. The time cost of deconvoluting all serum binders would be prohibitive. Our strategy still costs the time spent in screening the 45 compound mixtures, 6 times (Fig. 2) . However, in addition to allowing prioritization of hits and targets, the PCF list filtering also reduces the cost of retesting and deconvolution if the hits overlapping the PCF list are not pursued. For MurF, the initial list of 1147 unique compounds was reduced to 402 compounds by application of the promiscuous compound filter. This meant that only 30 mixtures of 13 compounds needed to be tested in the deconvolution step instead of 86 mixtures. At this rate, the investment in upfront promiscuous compound filtering is realized after screening just 5 targets. The research cost of attempting to optimize the chemically intractable compounds and targets that application of promiscuous compound filtering may eliminate, however, is likely to be much higher. Importantly, the PCF list is used to electronically filter hits as a means of prioritizing hits, but no information is lost. One can also choose to deconvolute those hits that overlap with the PCF list, with the expectation that many, but not all, of the hits identified will subsequently be shown to exhibit nonspecific protein binding, for example, compounds 1 through 3.
ASMS is applicable to combinatorial and traditional libraries of small molecules, peptides, and carbohydrates, although with libraries that may share some nonspecific affinity for particular targets, large mixtures should be tested to ensure that there is not significant aggregate binding of the mixture (discussed above). No protein tag or protein molecular weight constraints are required. Like other affinity techniques for HTS, ASMS identifies compounds that bind to a target without regard to function, and its speed, efficiency, and applicability to all soluble targets makes it appropriate for genomics and proteomics targets. Of note is the ligand confirmation efficiency built into the system. In most HTS screen formats, chemical matter showing activity or binding must be independently confirmed for structural integrity. 40 In ASMS, ligands are identified from their mass spectrometric peak position, so the only opportunity for misidentification is via a structural isomer. ASMS can be complementary to activity screening but also can be useful in identifying ligands for targets with particularly difficult or expensive activity assays. Although 1 novel class of MurF ligands discovered here clearly was optimizable for in vitro potency, no whole-cell antibacterial activity has been demonstrated for this series, even after steps were taken to address potential issues of cellular permeability and active transport of compounds out of the cell. 29 The discovery of the MurF ligands demonstrates the utility and advantages of the lead discovery methods described here.
EXPERIMENTAL PROCEDURES
Affinity selection
Streptococcus pneumoniae MurF was cloned into the pET-30 LIC vector (Novagen, San Diego) after PCR amplification from genomic DNA and expressed and purified as a recombinant protein in house at Abbott Laboratories (Abbott Park, IL). High-performance liquid chromatography (HPLC) grade water, methylene chloride, and methanol were purchased from EM Science (Gibbstown, NJ). Sodium chloride and Tris solution were purchased from Gibco BRL (Grand Island, NY). The compound library is composed of small molecules (average molecular weight approximately 330 Da) acquired through purchase from compound vendors, company mergers, and compound compilations from previous lead optimization efforts. Compound mixtures were prepared for screening by starting with single compounds dissolved to 5 mM in DMSO. Successive steps of mixing and either dry-downs or dilutions resulted in stocks of 30 µM each compound for dilution in primary screening samples and 112 µM each compound for dilution in retest/deconvolution screening samples. Protein target and compound mixtures were prepared for ASMS screening in 50 mM Tris buffer (pH 7.5) containing 150 mM NaCl and 2 mM 2-mercaptoethanol. The incubation mixtures, in which the final protein concentration was 10 µM and individual compound concentrations were 1.5 µM, were allowed to incubate at room temperature (RT) for 45 min. After centrifugation of the sample to remove particulates (16,100 rcf for 5 min), 400 µL of the mixtures was transferred to Microcon YM-10 units (Millipore Bedford, MA) and placed in a novel pressure-limited filtration device (custom, patent pending). Sufficient time for pressure equilibration (40-50 min) allowed a volume of 360 µL to be filtered through the 10,000 molecular weight cutoff membrane, leaving 40 µL on top of the filter. Considering some loss of protein to the filter, protein was added back in a buffer volume of 360 µL at 25% of the initial concentration, and mixtures were reincubated at RT for 30 min. Samples then were transferred to new Microcon units, and pressure filtration, dilution, and incubation were repeated. After a third filtration step, the final 40-µL retentate was transferred to a 96-deep-well plate (0.5 mL capacity per well [Costar, #3975, Corning, NY], prerinsed with methylene chloride and methanol) for extraction.
The free target concentration is in excess over individual ligands, so the amount of compound bound at equilibrium can be estimated according to equation 1. (1) K D can be estimated according to the following, where R0 and R3 represent either a raw signal intensity or signal to local background ratio: (2) (3) (4) During the deconvolution phase of screening, careful control of the pre-and postfiltration volumes are required to ensure both a rank ordering of binding strengths and estimation of the K D value. The postfiltration volumes are controlled by use of a pressure filtration device for selection steps. Operationally, all of R3 is sampled for analysis, and 10% of R0 is sampled. Therefore, when the compound K D is equal to the protein concentration, the R3 signal will be approximately equal to the R0 signal, and an R3 signal generated through selection in the absence of protein will be 100-fold (rather than 1000-fold) less than the R0 signal. Compounds whose K D values are 10-fold or more below the protein concentration appear as peaks with approximately 10 times the intensity of the R0 peak, assuming a linear dose response in the mass spectrometer. Using the example of a compound with K D = [protein] and a starting compound concentration of 1.5 µM in a volume of 400 µL, 75 pmol of compound remains after 3 rounds (600 pmol divided by 2, 3 times). Because the final samples are split into 3 aliquots, for positive ion analysis, negative ion analysis, and a backup sample as needed, approximately 25 pmol of material is available for analysis.
Serum preparation
Fetal calf serum (Gibco, catalog 16000-036) was decomplemented by heat inactivation and then dialyzed against a 10-kDa molecular weight cutoff dialysis membrane. Serum was dialyzed against 4 changes of buffer composed of 50 mM Tris (pH 7.5), 150 mM NaCl, and 2 mM 2-mercaptoethanol. Protein concentration was checked by Bradford assay and averaged 38 mg/mL. 
Solvent extraction
A total of 60 µL of methanol was added to the 40-µL samples from affinity selection to denature the protein and release bound compounds. These samples were extracted twice with 300 µL methylene chloride each, transferring the organic solution equally into 3 standard 96-well V-bottom polypropylene plates (0.25 mL capacity per well, prerinsed with methylene chloride and methanol). The samples were dried, then resuspended in 20 µL 50% methanol/water solution containing internal standards before mass spectrometry analysis.
Mass spectrometry
The 20-µL samples from solvent extraction were injected directly into a time-of-flight mass spectrometer (Waters LCT, Milford, MA) using an electrospray ionization source, an HPLC pump (Shimadzu CL-10ADvp, Columbia, MD), and an autosampler (Shimadzu SIL-10ADvp) at a flow rate of 150 µL per min. A mass range of 200 to 800 amu was used during routine detection; the analytical cycle time was 1.7 min per sample. Masslynx software (Waters, Milford, MA) was used for integration and visual inspection of peaks.
MurF enzyme assay
The assay has been described previously. 29 Briefly, the D-Ala-D-Ala adding activity of the enzyme was measured through the accompanying release of free radiolabeled inorganic phosphate from γ-labeled adenosine triphosphate (ATP).
